Dr. Klairmont is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
550 1st Ave
New York, NY 10016Phone+1 646-929-7800
Education & Training
Rush Medical College of Rush University Medical CenterClass of 2014
University of TennesseeResidency, Pathology-Anatomic and Clinical
Certifications & Licensure
NY State Medical License 2020 - 2026
PA State Medical License 2020 - 2021
Publications & Presentations
PubMed
- 23 citationsInterleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic MelanomaTasha Hughes, Matthew M. Klairmont, William H. Sharfman, Howard L. Kaufman
Cancer Biology & Therapy. 2021-11-19 - 6 citationsCo-occurring rearrangements of DUSP22 and TP63 define a rare genetic subset of ALK-negative anaplastic large cell lymphoma with inferior survival outcomes.Matthew M. Klairmont, Nicholas Ward
Leukemia & Lymphoma. 2021-10-06 - 2 citationsIn a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported.Tauangtham Anekpuritanang, Matthew M. Klairmont, Joel F. Gradowski, Kohei Hagiwara, Nathanael G. Bailey
Blood Advances. 2021-09-24
Journal Articles
- The Comparative Sensitivity of Immunohistochemical Markers of Megakaryocytic Differentiation in Acute Megakaryoblastic LeukemiaNour Yadak, Matthew M Klairmont, Deepthi Hoskoppal, American Journal of Clinical Pathology
Professional Memberships
- Society for Hematopathology - SHMember
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
